Unknown

Dataset Information

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.


ABSTRACT:

Background

Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). However, there are no clinical trials that have directly compared these agents. We conducted a systematic review and indirectly compared the efficacy of azacitidine to decitabine in MDS.

Methods

We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus) through June 28, 2018, without language or time restrictions. Studies were screened by two independent reviewers, and differences were resolved by consensus. The fixed effect model and adjusted indirect comparison methods were used to pool relative risks (RR) of major outcomes of interest (mortality, response r

SUBMITTER: Almasri J 

PROVIDER: S-EPMC6145118 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature